Improvement in scalp hair growth in androgen-deficient women treated with testosterone: A questionnaire study

British Journal of Dermatology

Volumn 166, Issue 2, 2012, Pages 274-278

  Glaser, R L ^a,b   Dimitrakakis, C ^c,d   Messenger, A G ^e  

^a Millennium Wellness Center   (United States)

^b WRIGHT STATE UNIVERSITY   (United States)

^c UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^d EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^e ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; TESTOSTERONE;

ADULT; ANDROGEN DEFICIENCY; ARTICLE; BODY MASS; CONTROLLED STUDY; HAIR; HAIR GROWTH; HAIR LOSS; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SCALP HAIR; TESTOSTERONE BLOOD LEVEL; TREATMENT DURATION;

ADMINISTRATION, CUTANEOUS; ALOPECIA; ANDROGENS; DRUG IMPLANTS; FEMALE; HAIR; HUMANS; MIDDLE AGED; PROSPECTIVE STUDIES; QUESTIONNAIRES; SCALP DERMATOSES; TESTOSTERONE; TREATMENT OUTCOME;

EID: 84856217209     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2011.10655.x     Document Type: Article

References (22)

1. Birch MP, Messenger JF, Messenger AG,. Hair density, hair diameter and the prevalence of female pattern hair loss. Br J Dermatol 2001; 144: 297-304.
2. Norwood OT,. Incidence of female androgenetic alopecia (female pattern alopecia). Dermatol Surg 2001; 27: 53-4.
3. Ludwig E,. Classification of the types of androgenetic alopecia (common baldness) occurring in the female sex. Br J Dermatol 1977; 97: 247-54.
4. Hamilton JB,. Male hormone stimulation is pre-requisite and an incitant in common baldness. Am J Anat 1942; 71: 451-80.
5. Imperato-McGinley J,. 5alpha-reductase-2 deficiency and complete androgen insensitivity: lessons from nature. Adv Exp Med Biol 2002; 511: 121-31, discussion 31-4.
6. Kaufman KD, Olsen EA, Whiting D, et al. Finasteride in the treatment of men with androgenetic alopecia. J Am Acad Dermatol 1998; 39: 578-89.
7. Olsen EA, Hordinsky M, Whiting D, et al. The importance of dual 5alpha-reductase inhibition in the treatment of male pattern hair loss: results of a randomized placebo-controlled study of dutasteride versus finasteride. J Am Acad Dermatol 2006; 55: 1014-23.
8. Glaser R, York AE, Dimitrakakis C,. Beneficial effects of testosterone therapy in women measured by the validated Menopause Rating Scale (MRS). Maturitas 2011; 68: 355-61.
9. Futterweit W, Dunaif A, Yeh HC, et al. The prevalence of hyperandrogenism in 109 consecutive female patients with diffuse alopecia. J Am Acad Dermatol 1988; 19: 831-6.
10. Vexiau P, Chaspoux C, Boudou P, et al. Role of androgens in female-pattern androgenetic alopecia, either alone or associated with other symptoms of hyperandrogenism. Arch Dermatol Res 2000; 292: 598-604.
11. Cela E, Robertson C, Rush K, et al. Prevalence of polycystic ovaries in women with androgenic alopecia. Eur J Endocrinol 2003; 149: 439-42.
12. Matilainen V, Laakso M, Hirsso P, et al. Hair loss, insulin resistance, and heredity in middle-aged women. A population-based study. J Cardiovasc Risk 2003; 10: 227-31.
13. Schmidt JB, Lindmaier A, Trenz A, et al. Hormone studies in females with androgenic hair loss. Gynecol Obstet Invest 1991; 31: 235-9.
14. Price VH, Roberts JL, Hordinsky M, et al. Lack of efficacy of finasteride in postmenopausal women with androgenetic alopecia. J Am Acad Dermatol 2000; 43: 768-76.
15. Vexiau P, Chaspoux C, Boudou P, et al. Effects of minoxidil 2% vs. cyproterone acetate treatment on female androgenetic alopecia: a controlled, 12-month randomized trial. Br J Dermatol 2002; 146: 992-9.
16. Carmina E, Lobo RA,. Treatment of hyperandrogenic alopecia in women. Fertil Steril 2003; 79: 91-5.
17. Acien P, Quereda F, Matallin P, et al. Insulin, androgens, and obesity in women with and without polycystic ovary syndrome: a heterogeneous group of disorders. Fertil Steril 1999; 72: 32-40.
18. Tomlinson JW, Finney J, Gay C, et al. Impaired glucose tolerance and insulin resistance are associated with increased adipose 11beta-hydroxysteroid dehydrogenase type 1 expression and elevated hepatic 5alpha-reductase activity. Diabetes 2008; 57: 2652-60.
19. Jakimiuk AJ, Weitsman SR, Magoffin DA,. 5alpha-reductase activity in women with polycystic ovary syndrome. J Clin Endocrinol Metab 1999; 84: 2414-18.
20. Nestler JE, Jakubowicz DJ, de Vargas AF, et al. Insulin stimulates testosterone biosynthesis by human thecal cells from women with polycystic ovary syndrome by activating its own receptor and using inositolglycan mediators as the signal transduction system. J Clin Endocrinol Metab 1998; 83: 2001-5.
21. Davison SL, Bell R, Donath S, et al. Androgen levels in adult females: changes with age, menopause, and oophorectomy. J Clin Endocrinol Metab 2005; 90: 3847-53.
22. Zumoff B, Strain GW, Miller LK, et al. Twenty-four-hour mean plasma testosterone concentration declines with age in normal premenopausal women. J Clin Endocrinol Metab 1995; 80: 1429-30.